aripiprazole has been researched along with Obesity in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (51.52) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SY; Jang, S; Kim, DG; Kim, J; Kim, S; Lee, CH; Lee, KW; Lee, N; Park, JK; Suh, SB | 1 |
| Bennett, CW; Gensler, L; Goldsmith, DR | 1 |
| Ivanov, I; Nicol, GE | 1 |
| Cortes, ND; Duan, L; Guber, KM | 1 |
| Anagnostou, E | 1 |
| Arnoldy, R; Curtis, J; Samaras, K | 1 |
| Danilov, DS | 1 |
| Liu, J; Meng, X; Xia, SY; Yu, H; Zhang, P; Zhang, YR | 1 |
| Chang, KD | 1 |
| Findling, RL | 1 |
| Erickson, CA; McDougle, CJ; Posey, DJ; Stigler, KA | 1 |
| Berman, RM; Breder, C; Campos, JA; Carson, WH; Kerselaers, W; L'italien, GJ; Marcus, RN; McQuade, RD; Newcomer, JW; Nys, M | 1 |
| Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
| Bogers, JP; Starrenburg, FC | 1 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Evins, AE; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B | 1 |
| Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H | 1 |
| McIntyre, RS | 1 |
| Radics, J | 1 |
| Deng, C; Huang, XF; Lian, J; Pai, N | 1 |
| Chen, J; Deng, C; Hu, C; Huang, XF | 1 |
| Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D | 1 |
| Coffey, DB; John, N; Potter, PO | 1 |
| Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
| Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S | 1 |
| Connor, KM; Davidson, JR; Gadde, KM; Payne, VM; Zhang, W | 1 |
| Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
| Chen, CK; Lin, SK | 1 |
| Wooten, J | 1 |
| Chen, CH; Huang, MC; Lu, ML | 1 |
| Corey-Lisle, PK; Crosby, RD; Kan, HJ; Kolotkin, RL; McQuade, RD | 1 |
9 review(s) available for aripiprazole and Obesity
| Article | Year |
|---|---|
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Depressants; Central Nervous System Stimulants; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Irritable Mood; Melatonin; Metformin; Methylphenidate; Obesity; Outcome Assessment, Health Care; Precision Medicine; Risperidone; Sleep; Sleep Wake Disorders | 2018 |
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Comorbidity; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Weight Gain | 2008 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Child; Dibenzothiazepines; Disorders of Excessive Somnolence; Headache; Humans; Methylphenidate; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2008 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Clozapine; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2008 |
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.
Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain | 2009 |
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult | 2009 |
Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Metabolic Diseases; Obesity; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
8 trial(s) available for aripiprazole and Obesity
| Article | Year |
|---|---|
[The use of aripiprazole in the treatment of obesity associated with the administration of neuroleptics of the second generation in patients with schizophrenia].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Obesity; Piperazines; Quinolones; Schizophrenia; Withholding Treatment | 2014 |
[Treatment of antipsychotic drug-induced phlegm dampness type amenorrhea by Wuji Powder and a small dose aripiprazole: a clinical study].
Topics: Aged; Amenorrhea; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Galactorrhea; Humans; Obesity; Piperazines; Quinolones; Waist-Hip Ratio | 2014 |
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2008 |
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; C-Reactive Protein; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Glucose; Humans; Male; Middle Aged; Obesity; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Triglycerides | 2009 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperazines; Quinolones; Time Factors; Treatment Outcome; Triazines; Valproic Acid | 2013 |
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain | 2004 |
The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Nausea; Obesity; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Weight Gain | 2005 |
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Dose-Response Relationship, Drug; Europe; Female; Humans; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Quality of Life; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Self Concept; Social Adjustment | 2008 |
16 other study(ies) available for aripiprazole and Obesity
| Article | Year |
|---|---|
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Female; Hypothalamus; Leptin; Metformin; Mice; Neurons; Obesity; Olanzapine; Pro-Opiomelanocortin | 2022 |
Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic.
Topics: Antipsychotic Agents; Aripiprazole; Comorbidity; Cross-Sectional Studies; Humans; Obesity; Outpatients; Retrospective Studies | 2023 |
Getting to Precision Psychopharmacology in Child Psychiatry: The Value of Adverse Treatment Effects.
Topics: Antipsychotic Agents; Aripiprazole; Child; Child Psychiatry; Drug-Related Side Effects and Adverse Reactions; Humans; Obesity; Precision Medicine; Psychopharmacology; Risperidone | 2021 |
Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Humans; Infant; Male; Obesity; Retrospective Studies; Risperidone | 2022 |
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss | 2014 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses | 2010 |
Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Schizophrenia | 2010 |
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2010 |
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia | 2011 |
Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
Topics: Adrenergic alpha-Agonists; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Asthma; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Chest Pain; Child; Dyskinesia, Drug-Induced; Family; Female; Guanfacine; Humans; Lithium Chloride; Male; Mood Disorders; Neuropsychological Tests; Obesity; Paroxetine; Piperazines; Polypharmacy; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Agitation; Quinolones; Selective Serotonin Reuptake Inhibitors; Smoking; Social Environment | 2012 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Risperidone; Schizophrenia, Paranoid; Treatment Outcome; Weight Gain | 2006 |
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2007 |